Final-Program-ATS-2023-AP.vp

200

MONDAY • MAY 22

Objectives At the conclusion of this session, the participant will be able to: • describe new technologies that allow assessment of gene expression at the cellular and lesional level from animals and patients with pulmonary vascular disease • apply new technologies for assessing cell specific gene expression to advance basic science research in pulmonary vascular biology • apply new knowledge competence to better understand the pathophysiology of pulmonary vascular disease to help guide the diagnosis and treatment of pulmonary arterial hypertension New techniques in RNA sequencing, spatial tanscriptomics and proteomics have rapidly developed and allow for assessment of near complete gene expression at a microscopic lesional, and cellular level, focused on a precise area of interest making it possible to compare gene expression between different types of pulmonary vascular cells under baseline and disease conditions. This symposium will present novel findings from multiple laboratories demonstrating how these techniques are moving the field of pulmonary vascular biology forward, with a focus on methodology development, the required expertise to carry out such an analyses, bioinformatics, and interpretation of the data. Chairing: J.R. Klinger, MD, ATSF, Providence, RI J. Leopold, MD, Boston, MA M.W. Geraci, MD, Pittsburgh, PA 2:15 Integrated Analysis of scRNAseq Data Sets to Develop a Comprehensive Atlas of Endothelial Gene Expression in the Normal Lung N. Kaminski, MD, ATSF, New Haven, CT 2:35 Reactivation of Transcriptional Programs That Orchestrate Fetal Lung Development in Human Pulmonary Hypertension S.S. Pullamsetti, PhD, Bad Nauheim, Germany 2:50 The Use of Single-Cell Transcriptomics in Animal Models of Pulmonary Hypertension to Identify Genetic Changes Relevant to Human Pulmonary Hypertension J. Hong, MD, PhD, Los Angeles, CA 3:10 Combining Spatial Transcriptomics and Single Cell RNAseq to Examine Gene Expression in Pulmonary Vasculature Endothelial Cells A. Brodsky, PhD, Providence, RI 3:30 Use of Spatial Transcriptomics to Examine Lesion Specific Gene Expression in Human Pulmonary Arterial Hypertension K.R. Stenmark, MD, Aurora, CO

• describe approaches and participate in effective advocacy to reduce the carbon footprint of healthcare both at a provider and system level Climate change threatens human health with a disproportionate burden on vulnerable populations. Human activities contributing to climate change include burning of biomass fuels and resultant emission of greenhouse gasses. A ‘carbon footprint’ reflects the effect that a person, group of people, or industry has on emissions. Healthcare providers and systems directly contribute to and treat climate change’s negative effects on health. Thus we are both responsible for and uniquely poised to take a leadership role in individual and industry response to the climate crisis. Presented are multiple potential points of healthcare system intervention to reduce the pace of global warming. Chairing: E. Brigham, MD, MHS, Vancouver, Canada J.M. Radbel, MD, New Brunswick, NJ J.P. Castner, PhD, RN, Grand Island, NY M.B. Rice, MD, MPH, Boston, MA 2:15 Scope of the Problem: Healthcare Sector Pollution and Climate Change J. Sherman, MD, New Haven, CT 2:35 Changing How We Work: Hospital Operations H. Shankar, MD, Philadelphia, PA 2:50 Treatment Choices: A Case Study in Inhalers A. Rabin, MD, Ann Arbor, MI 3:05 The Commute: Implementing Climate Action Plans for Transportation R.J. Laumbach, MD, MPH, Piscataway, NJ 3:20 We have an Important Voice: Care Providers as Climate Actors Speaker To Be Announced 3:35 Group Discussion TRANSCRIPTOMIC PROFILING OF PULMONARY VASCULAR LESIONS UNRAVEL MECHANISMS OF PULMONARY ARTERIAL HYPERTENSION Assemblies on Pulmonary Circulation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function 2:15 PM - 3:45 PM Walter E. Washington Convention Center Room 207 A-B (Level 2) Target Audience Investigators and physician scientists interested in advanced techniques used to explore molecular mechanisms of pulmonary vascular remodeling, as well as clinicians, pharmacists and other caregivers engaged in treating patients with pulmonary hypertensio BASIC • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 1.5 B89

This session and the International Conference are supported by an independent medical educational grant from Merck & Co. and United Therapeutics Corporation.

All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

ATS 2023 • Washington, DC